Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701245 | 1.00 | MAPT (0.43) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL4699459 | 0.85 | MAPT (0.49) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL4701250 | 0.80 | KMT2A (0.43) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL398854 | 0.78 | MAPT (0.48) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL398853 | 0.78 | MAPT (0.48) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL4697709 | 0.76 | MAPT (0.51) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL4697713 | 0.76 | MAPT (0.51) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL4699456 | 0.76 | LMNA (0.44) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL4699454 | 0.76 | LMNA (0.44) | MAPTLMNAKDM4EHPGDPOLB | |
| SCHEMBL529833 | 0.74 | MAPT (0.55) | MAPTLMNAKDM4EHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309544-B1 | COMPOUNDS ACTING AS MELANOCORTIN RECEPTOR LIGANDS | ACURE PHARMA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-7153881-B2 | Compounds acting as melanocortin receptor ligands | ACURE PHARMA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20040019094-A1 | Compounds acting as melanocortin receptor ligands | HPF IP HOLDING S.A. (LU) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019094-A1 | Compounds acting as melanocortin receptor ligands | MC1R, MC3R, MC5R | MAPT 3667/4885LMNA 2921/4885KDM4E 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.